Vivek Subbiah, MD | UniHealth

Medicare standing: Clear; Enrolled, allowed to bill and order, not excluded
Plans that list them: 13; 2 carriers
Offices: 2

Offices

2 locations · Stanford Health Care · Verdi Oncology Tennessee PC

Looking this up.

Plans that list them

13 plans · 2 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Subbiah’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

13 of 13 plans

Sort by

Plans whose provider directory lists this clinician

Alignment Health BreathEasy (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Clarity (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Harmony (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)	Alignment Health Plan	Listed	Sep 28, 2026
Alignment Health Honor+ Plan (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health My Choice CalCare (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health Silicon (HMO C-SNP)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health smartHMO (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
Alignment Health the ONE (HMO)	Alignment Health Plan	Listed	Oct 3, 2026
DualConnect (HMO D-SNP)	Santa Clara Family Health Plan	Listed	Sep 1, 2026

State licence records

1 licence

Texas N6693Physician License · since 2010 · expires 2025-11-30
Delinquent - Incomplete RegistrationNo board action on this licenceCheck it with the state

We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.

Original Medicare doctor bills

$321,977

Medicare paid this office $321,977 for 67 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Sort by

Largest Original Medicare bills

Long return visit (40+ min)	13	$8,056	$132
Administration of chemotherapy into vein, 1 hour or less	29	$3,807	$87
New patient visit (60+ min)	18	$2,897	$161
Insertion of needle into vein for collection of blood sample	19	$1,012	$9
Blood test, comprehensive group of blood chemicals	12	$735	$10

See all 9 services

Sort by

Every Original Medicare service billed

Long return visit (40+ min)	13	$8,056	$132
Administration of chemotherapy into vein, 1 hour or less	29	$3,807	$87
New patient visit (60+ min)	18	$2,897	$161
Insertion of needle into vein for collection of blood sample	19	$1,012	$9
Blood test, comprehensive group of blood chemicals	12	$735	$10
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	17	$639	$8
Injection of additional new drug or substance into vein	15	$426	$11
Infusion, normal saline solution , 1000 cc	18	$52	None
Injection, dexamethasone sodium phosphate, 1 mg	13	$16	None

Who their Medicare patients are

67 Original Medicare patients in 2024. Average age 69 · Women 54% · Health risk score 2.50. Above the middle of the specialty; the typical hematology-oncology clinician is at 2.04.

Conditions among them: High blood pressure 70% · Cancer 60% · Depression 25% · Coronary heart disease 24% · Diabetes 18% · Chronic kidney disease 16%.

The office billed $1,201,042, Medicare allowed $402,702 and paid $321,977; for 9,527 services of 70 kinds; $300,065 of it was for drugs given in the office and $21,912 for care.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Sort by

Original Medicare by year

2024	67	9,527	69	2.50	$1,201,042	$321,977
2023	97	242	66	3.50	$113,873	$23,262
2022	168	595	68	2.95	$264,792	$61,797
2021	128	643	67	2.88	$277,038	$67,999
2020	120	484	68	3.40	$188,389	$40,700
2019	179	555	66	3.14	$244,487	$51,169
2018	198	668	67	3.28	$293,350	$60,048
2017	207	677	67	3.30	$292,492	$60,113
2016	158	406	66	3.37	$168,056	$36,382
2015	183	464	66	3.00	$199,154	$43,160
2014	158	471	65	2.87	$192,871	$44,345
2013	123	406	65	2.47	$165,828	$36,828

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 2 services

Sort by

Original Medicare services billed in 2023

Long return visit (40+ min)	83	$19,126	$105
Telephone medical discussion with physician, 11-20 minutes	11	$872	$48

2022: 5 services

Sort by

Original Medicare services billed in 2022

Long return visit (40+ min)	144	$48,018	$113
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$4,334	$83
Telephone medical discussion with physician, 11-20 minutes	37	$3,062	$55
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$2,824	$157
Telephone medical discussion with physician, 21-30 minutes	12	$1,454	$81

2021: 3 services

Sort by

Original Medicare services billed in 2021

Long return visit (40+ min)	110	$56,444	$117
Telephone medical discussion with physician, 11-20 minutes	30	$3,249	$56
Telephone medical discussion with physician, 21-30 minutes	24	$2,892	$74

2020: 6 services

Sort by

Original Medicare services billed in 2020

Long return visit (40+ min)	87	$23,213	$87
Return visit (30+ min)	35	$6,438	$64
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	20	$3,537	$86
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$3,165	$167
Hospital discharge day management, more than 30 minutes	17	$1,500	$88
Telephone medical discussion with physician, 21-30 minutes	11	$856	$66

2019: 5 services

Sort by

Original Medicare services billed in 2019

Long return visit (40+ min)	134	$38,401	$88
New patient visit (60+ min)	36	$4,835	$134
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	18	$4,776	$85
Initial hospital care with moderate level of medical decision making at least 75 minutes	12	$1,801	$150
Hospital discharge day management, more than 30 minutes	15	$1,251	$83

2018: 5 services

Sort by

Original Medicare services billed in 2018

Long return visit (40+ min)	154	$45,758	$85
New patient visit (60+ min)	38	$5,120	$135
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	21	$4,712	$83
Initial hospital care with moderate level of medical decision making at least 75 minutes	20	$3,308	$158
Hospital discharge day management, more than 30 minutes	13	$1,150	$82

2017: 5 services

Sort by

Original Medicare services billed in 2017

Long return visit (40+ min)	150	$44,373	$85
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	31	$5,861	$79
New patient visit (60+ min)	39	$4,756	$122
Initial hospital care with moderate level of medical decision making at least 75 minutes	24	$3,477	$145
Hospital discharge day management, more than 30 minutes	17	$1,444	$85

2016: 5 services

Sort by

Original Medicare services billed in 2016

Long return visit (40+ min)	106	$21,943	$85
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	32	$5,671	$77
New patient visit (60+ min)	29	$3,746	$129
Initial hospital care with moderate level of medical decision making at least 75 minutes	18	$3,021	$159
Hospital discharge day management, more than 30 minutes	11	$925	$84

2015: 5 services

Sort by

Original Medicare services billed in 2015

Long return visit (40+ min)	136	$29,301	$88
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	24	$4,686	$84
New patient visit (60+ min)	35	$4,634	$132
Initial hospital care with moderate level of medical decision making at least 75 minutes	19	$3,106	$155
Hospital discharge day management, more than 30 minutes	12	$1,035	$86

2014: 5 services

Sort by

Original Medicare services billed in 2014

Long return visit (40+ min)	104	$24,191	$87
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	33	$7,253	$82
Initial hospital care with moderate level of medical decision making at least 75 minutes	33	$6,452	$161
New patient visit (60+ min)	32	$4,210	$132
Hospital discharge day management, more than 30 minutes	19	$1,689	$77

2013: 5 services

Sort by

Original Medicare services billed in 2013

Long return visit (40+ min)	78	$21,584	$84
Subsequent hospital care with moderate levelof medical decision making at least 50 minutes	22	$5,088	$80
Initial hospital care with moderate level of medical decision making at least 75 minutes	25	$4,227	$151
New patient visit (60+ min)	31	$4,035	$130
Hospital discharge day management, more than 30 minutes	20	$1,664	$79

Money from drug and device companies

$48,973 in 2025

Sort by

Industry payments by year

2025	22	74	$40,335	$48,973
2024	17	35	$17,020	$19,081
2023	13	20	$22,483	$24,690
2022	6	11	$43,221	$43,304
2021	7	10	$19,903	$19,903
2020	3	5	$18,780	$18,822
2019	7	18	$9,350	$19,301

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Sort by

Payments by company

E.R. Squibb & Sons L.L.C.	Opdualag	$20,633	19 payments Consulting · 2025-10-14 · $12,889 Meals · 2025-09-03 · $65 Meals · 2025-09-03 · $15 Meals · 2025-09-03 · $145 Meals · 2025-09-03 · $30 Meals · 2025-09-03 · $30 Travel · 2025-09-03 · $38 Travel · 2025-09-03 · $324 Meals · 2025-09-03 · $30 Travel · 2025-09-03 · $387 Meals · 2025-09-03 · $50 Meals · 2025-09-03 · $50 Meals · 2025-09-03 · $65 Meals · 2025-09-03 · $149 Travel · 2025-09-03 · $20 Travel · 2025-09-02 · $387 Meals for Opdualag · 2025-08-25 · $24 Consulting · 2025-04-21 · $508 Travel · 2025-03-21 · $5,427
Pfizer	Litfulo	$6,148	6 payments Consulting for Litfulo · 2025-11-05 · $2,160 Meals for Lorbrena · 2025-10-20 · $70 Consulting · 2025-09-25 · $1,950 Meals for Ibrance · 2025-09-17 · $18 Consulting for Braftovi · 2025-07-09 · $1,800 Meals for Padcev · 2025-06-02 · $150
AstraZeneca Pharmaceuticals LP	Datroway	$5,947	5 payments Meals · 2025-06-11 · $23 Meals · 2025-06-02 · $76 Consulting · 2025-05-02 · $3,280 Meals for Datroway · 2025-04-27 · $108 Consulting for Datroway · 2025-01-10 · $2,460
Rigel Pharmaceuticals	Gavreto	$3,517	3 payments Honoraria for Gavreto · 2025-06-12 · $3,425 Meals for Gavreto · 2025-05-30 · $71 Meals for Tavalisse · 2025-05-27 · $21
Abbvie	None	$2,968	2 payments Meals · 2025-05-29 · $68 Consulting · 2025-03-13 · $2,900
Incyte	None	$2,859	2 payments Consulting · 2025-06-06 · $2,842 Meals · 2025-05-03 · $17

See all 74 published payments

Sort by

Every published payment

Invivyd	Meals · 2025-12-15	Pemgarda	$20
Array Biopharma	Meals · 2025-12-10	Xtandi	$19
Recordati Rare Diseases Inc.	Meals · 2025-11-21	Enjaymo	$33
Novartis Pharmaceuticals	Meals · 2025-11-19	Pluvicto	$28
Pfizer	Consulting · 2025-11-05	Litfulo	$2,160
Daiichi Sankyo	Meals · 2025-11-02	None	$30
Pfizer	Meals · 2025-10-20	Lorbrena	$70
E.R. Squibb & Sons L.L.C.	Consulting · 2025-10-14	None	$12,889
Merck Sharp & Dohme	Meals · 2025-10-08	Keytruda	$23
Pfizer	Consulting · 2025-09-25	None	$1,950
Novartis Pharmaceuticals	Meals · 2025-09-24	Kisqali	$27
Bayer Healthcare Pharmaceuticals	Consulting · 2025-09-17	None	$686
Bayer Healthcare Pharmaceuticals	Consulting · 2025-09-17	None	$686
Pfizer	Meals · 2025-09-17	Ibrance	$18
Daiichi Sankyo	Meals · 2025-09-12	Enhertu	$24
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$65
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$15
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$145
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$30
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$30
E.R. Squibb & Sons L.L.C.	Travel · 2025-09-03	None	$38
E.R. Squibb & Sons L.L.C.	Travel · 2025-09-03	None	$324
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$30
E.R. Squibb & Sons L.L.C.	Travel · 2025-09-03	None	$387
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$50
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$50
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$65
E.R. Squibb & Sons L.L.C.	Meals · 2025-09-03	None	$149
E.R. Squibb & Sons L.L.C.	Travel · 2025-09-03	None	$20
E.R. Squibb & Sons L.L.C.	Travel · 2025-09-02	None	$387
E.R. Squibb & Sons L.L.C.	Meals · 2025-08-25	Opdualag	$24
Celgene	Meals · 2025-08-18	Abecma	$16
Array Biopharma	Meals · 2025-08-18	Braftovi	$36
BeOne Medicines USA	Meals · 2025-08-14	Tevimbra	$24
Novartis Pharmaceuticals	Meals · 2025-08-11	Kisqali	$30
SpringWorks Therapeutics	Meals · 2025-07-31	Gomekli	$24
Regeneron Healthcare Solutions	Meals · 2025-07-18	Libtayo	$33
Celgene	Meals · 2025-07-14	Breyanzi	$17
Pfizer	Consulting · 2025-07-09	Braftovi	$1,800
Novartis Pharmaceuticals	Meals · 2025-06-24	Kisqali	$31
AstraZeneca UK	Consulting · 2025-06-23	Enhertu	$2,050
Eisai	Meals · 2025-06-23	Lenvima	$24
Celgene	Meals · 2025-06-16	Breyanzi	$20
Rigel Pharmaceuticals	Honoraria · 2025-06-12	Gavreto	$3,425
AstraZeneca Pharmaceuticals LP	Meals · 2025-06-11	None	$23
Incyte	Consulting · 2025-06-06	None	$2,842
AstraZeneca Pharmaceuticals LP	Meals · 2025-06-02	None	$76
Pfizer	Meals · 2025-06-02	Padcev	$150
Rigel Pharmaceuticals	Meals · 2025-05-30	Gavreto	$71
Abbvie	Meals · 2025-05-29	None	$68
Rigel Pharmaceuticals	Meals · 2025-05-27	Tavalisse	$21
Janssen Biotech	Meals · 2025-05-16	Rybrevant	$19
Array Biopharma	Meals · 2025-05-05	Xtandi	$18
Incyte	Meals · 2025-05-03	None	$17
AstraZeneca Pharmaceuticals LP	Consulting · 2025-05-02	None	$3,280
Celgene	Meals · 2025-05-01	Breyanzi	$18
Merck Sharp & Dohme	Meals · 2025-04-29	Keytruda	$27
Daiichi Sankyo	Meals · 2025-04-28	Enhertu	$26
AstraZeneca Pharmaceuticals LP	Meals · 2025-04-27	Datroway	$108
E.R. Squibb & Sons L.L.C.	Consulting · 2025-04-21	None	$508
Novartis Pharmaceuticals	Meals · 2025-04-18	Lutathera	$14
SpringWorks Therapeutics	Meals · 2025-04-15	Gomekli	$20
Iovance Biotherapeutics	Meals · 2025-04-02	Amtagvi	$21
Daiichi Sankyo	Meals · 2025-03-24	Enhertu	$26
E.R. Squibb & Sons L.L.C.	Travel · 2025-03-21	None	$5,427
Abbvie	Consulting · 2025-03-13	None	$2,900
Novartis Pharmaceuticals	Meals · 2025-02-05	Pluvicto	$15
Regeneron Healthcare Solutions	Meals · 2025-02-03	Libtayo	$31
Array Biopharma	Meals · 2025-01-31	Bosulif	$22
Daiichi Sankyo	Meals · 2025-01-29	Enhertu	$24
Novartis Pharma AG	Consulting · 2025-01-28	Mekinist	$2,700
SpringWorks Therapeutics	Meals · 2025-01-16	None	$22
AstraZeneca Pharmaceuticals LP	Consulting · 2025-01-10	Datroway	$2,460
Celgene	Meals · 2025-01-09	Opdivo	$18

See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $19,081

Sort by

Payments by company in 2024

Pfizer	Lorbrena	$6,364	5 payments Consulting · 2024-10-01 · $1,800 Meals · 2024-09-13 · $62 Consulting · 2024-06-18 · $2,400 Meals · 2024-05-31 · $77 Paid to speak or teach for Lorbrena · 2024-01-10 · $2,025
Novartis Pharmaceuticals	Mekinist	$4,986	6 payments Meals for Lutathera · 2024-12-17 · $14 Meals for Pluvicto · 2024-09-11 · $20 Meals for Kisqali · 2024-07-08 · $29 Meals for Kisqali · 2024-06-13 · $28 Meals for Lutathera · 2024-06-11 · $20 Consulting for Mekinist · 2024-01-10 · $4,875
Lilly USA	Retevmo	$3,250	1 payment Consulting for Retevmo · 2024-06-10 · $3,250
Eli Lilly and	None	$2,735	6 payments Consulting · 2024-04-11 · $1,300 Travel · 2024-01-18 · $359 Travel · 2024-01-18 · $59 Travel · 2024-01-18 · $359 Travel · 2024-01-18 · $59 Travel · 2024-01-18 · $599
AstraZeneca Pharmaceuticals LP	Tagrisso	$1,422	3 payments Meals for Tagrisso · 2024-08-02 · $19 Meals for Tagrisso · 2024-04-26 · $33 Consulting for Tagrisso · 2024-02-14 · $1,370
Abbvie	None	$53	1 payment Meals · 2024-05-30 · $53
Daiichi Sankyo	Enhertu	$45	2 payments Meals for Enhertu · 2024-12-12 · $28 Meals for Enhertu · 2024-03-28 · $18
E.R. Squibb & Sons L.L.C.	Opdivo	$37	2 payments Meals for Krazati · 2024-12-19 · $18 Meals for Opdivo · 2024-04-25 · $19
Tempus AI	None	$30	1 payment Meals · 2024-10-07 · $30
Merck Sharp & Dohme	Keytruda	$29	1 payment Meals for Keytruda · 2024-08-27 · $29
Deciphera Pharmaceuticals	Qinlock	$22	1 payment Meals for Qinlock · 2024-03-18 · $22
Boehringer Ingelheim Pharmaceuticals	Gilotrif	$20	1 payment Meals for Gilotrif · 2024-11-14 · $20
Gilead Sciences	None	$19	1 payment Meals · 2024-09-05 · $19
TerSera Therapeutics	Zoladex	$18	1 payment Meals for Zoladex · 2024-04-11 · $18
SpringWorks Therapeutics	Ogsiveo	$18	1 payment Meals for Ogsiveo · 2024-10-03 · $18
EMD Serono	None	$17	1 payment Meals · 2024-03-19 · $17
Sun Pharmaceutical Industries	Yonsa	$15	1 payment Meals for Yonsa · 2024-08-16 · $15

2023: $24,690

Sort by

Payments by company in 2023

F. Hoffmann-La Roche AG	None	$14,076	4 payments Consulting · 2023-12-02 · $2,280 Meals · 2023-10-23 · $16 Consulting · 2023-10-23 · $8,740 Consulting · 2023-10-11 · $3,040
Pfizer	None	$2,469	3 payments Consulting · 2023-12-22 · $600 Consulting · 2023-11-08 · $1,800 Meals · 2023-10-21 · $69
Otsuka Pharmaceutical Co.	None	$2,363	2 payments Travel · 2023-10-12 · $1,363 Consulting · 2023-10-11 · $1,000
Regeneron Pharmaceuticals	None	$1,762	1 payment Consulting · 2023-09-22 · $1,762
Bayer Healthcare Pharmaceuticals	None	$1,346	1 payment Consulting · 2023-05-31 · $1,346
Janssen Pharmaceuticals	None	$1,240	1 payment Consulting · 2023-03-31 · $1,240
Novartis Pharmaceuticals	None	$675	1 payment Consulting · 2023-12-19 · $675
E.R. Squibb & Sons L.L.C.	None	$531	1 payment Travel · 2023-10-30 · $531
Foundation Medicine	None	$94	1 payment Meals · 2023-02-06 · $94
AbbVie	None	$65	2 payments Meals · 2023-10-19 · $43 Meals · 2023-10-19 · $22
Regeneron Healthcare Solutions	Libtayo	$32	1 payment Meals for Libtayo · 2023-12-22 · $32
Gilead Sciences	None	$22	1 payment Meals · 2023-12-20 · $22
Lilly USA	Verzenio	$15	1 payment Meals for Verzenio · 2023-07-27 · $15

2022: $43,304

Sort by

Payments by company in 2022

Jazz Pharmaceuticals	Zepzelca	$19,080	4 payments Consulting for Zepzelca · 2022-12-15 · $2,560 Consulting · 2022-11-18 · $3,720 Consulting for Zepzelca · 2022-07-05 · $9,600 Consulting for Zepzelca · 2022-06-01 · $3,200
Incyte	None	$16,614	1 payment Paid to speak or teach · 2022-08-12 · $16,614
Pfizer	None	$4,475	2 payments Consulting · 2022-06-27 · $2,475 Honoraria · 2022-03-18 · $2,000
Eisai	None	$2,040	1 payment Consulting · 2022-10-05 · $2,040
Illumina	Oncology Testing	$1,012	1 payment Paid to speak or teach for Oncology Testing · 2022-10-25 · $1,012
Blueprint Medicines	None	$83	2 payments Meals · 2022-09-29 · $49 Meals · 2022-09-29 · $34

2021: $19,903

Sort by

Payments by company in 2021

Eli Lilly and	None	$5,600	2 payments Consulting · 2021-09-22 · $2,450 Paid to speak or teach · 2021-09-14 · $3,150
F. Hoffmann-La Roche AG	Alecensa	$4,465	3 payments Consulting · 2021-11-24 · $1,000 Consulting for Alecensa · 2021-09-24 · $2,145 Consulting for Alecensa · 2021-09-24 · $1,320
Eisai	Lenvima	$3,125	1 payment Consulting for Lenvima · 2021-08-10 · $3,125
AstraZeneca Pharmaceuticals LP	Imfinzi	$2,740	1 payment Consulting for Imfinzi · 2021-02-22 · $2,740
AstraZeneca UK	None	$1,713	1 payment Consulting · 2021-08-12 · $1,713
Novartis Pharmaceuticals	Kisqali	$1,250	1 payment Paid to speak or teach for Kisqali · 2021-09-21 · $1,250
Janssen Scientific Affairs	None	$1,010	1 payment Consulting · 2021-11-11 · $1,010

2020: $18,822

Sort by

Payments by company in 2020

Eli Lilly and	None	$13,300	2 payments Paid to speak or teach · 2020-11-06 · $10,500 Consulting · 2020-09-17 · $2,800
Daiichi Sankyo	Enhertu	$5,480	1 payment Consulting for Enhertu · 2020-10-29 · $5,480
Exelixis	Cabozantinib	$42	2 payments Meals for Cabozantinib · 2020-03-17 · $22 Meals for Cabozantinib · 2020-03-17 · $20

2019: $19,301

Sort by

Payments by company in 2019

Helsinn Healthcare SA	None	$10,631	6 payments Travel · 2019-09-06 · $362 Meals · 2019-09-06 · $28 Consulting · 2019-09-06 · $2,000 Travel · 2019-09-06 · $102 Meals · 2019-09-06 · $37 Travel · 2019-09-06 · $8,103
Incyte	None	$7,129	5 payments Consulting · 2019-11-21 · $6,150 Meals · 2019-08-28 · $5 Travel · 2019-08-27 · $293 Travel · 2019-08-27 · $556 Travel · 2019-08-27 · $125
R-Pharm US	Ixempra	$1,306	2 payments Meals for Ixempra · 2019-09-24 · $106 Consulting for Ixempra · 2019-09-24 · $1,200
F. Hoffmann-La Roche AG	Non-Covered Product	$100	1 payment Meals for Non-Covered Product · 2019-06-01 · $100
Eli Lilly and	None	$56	2 payments Meals · 2019-09-30 · $36 Meals · 2019-09-23 · $20
Amgen	None	$44	1 payment Meals · 2019-06-02 · $44
Novartis Pharmaceuticals	None	$35	1 payment Meals · 2019-12-15 · $35

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Sort by

Research payments by company and study

Novartis Pharmaceuticals Corporation · Roar A Phase II Open Label Study in Subjects With Braf V600e Mutated Rare Cancers With Several Histologies To Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib · 2019	Their institution	$1,705,461
Novartis Pharmaceuticals Corporation · Roar A Phase II Open Label Study in Subjects With Braf V600e Mutated Rare Cancers With Several Histologies To Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib · 2020	Their institution	$919,016
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2020	Their institution	$817,220
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2019	Their institution	$804,778
AbbVie, Inc. · 2019	Their institution	$800,143
Blueprint Medicines Corporation · 2020	Their institution	$745,099
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2021	Their institution	$617,126
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2022	Their institution	$573,567
PFIZER INC. · A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies · 2023	Their institution	$535,532
PFIZER INC. · A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies · 2022	Their institution	$493,461
Amgen Inc. · P1b/2 Solid Tumor Hepatic Injection Safety. · 2019	Their institution	$422,675
Incyte Corporation · A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of Incb054828 in Subjects With Advanced Malignancies · 2019	Their institution	$407,026
PFIZER INC. · A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies · 2021	Their institution	$375,546
Incyte Corporation · Phase 12 Study Exploring the Safety, Tolerability, and Efficacy of Incagn01876 Combined With Immune Therapies in Advanced Or Metastatic Malignancies · 2019	Their institution	$351,995
Bayer HealthCare Pharmaceuticals Inc. · Bay1129980; Dose Escal. St. Plus 3 Ext. Cohorts · 2019	Their institution	$339,485
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors Including Ret Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With Ret Activation (Libretto-001) · 2023	Their institution	$335,882
GlaxoSmithKline, LLC. · A Phase 1 Clinical Study To Evaluate the Safety, Tolerability, Pharmac · 2025	Their institution	$320,709
Incyte Corporation · An Open-Label Assessment of the Effects of Various Degrees of Renal Impairment on the Pharmacokinetics of A Single 10mg Dose of Incb028050 Compared To Normal Healthy Adult Volunteers · 2020	Their institution	$307,005
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-260 in Patients With Ret Fusion-Positive Solid Tumors Medullary Thyroid Cancer and Other Tumors With Ret Activation Refractory To Selective Ret Inhibitors · 2023	Their institution	$289,445
Blueprint Medicines Corporation · Phase 1/2 Study of the Highly-Selective Ret Inhibitor, Pralsetinib (Blu-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (Arrow) · 2022	Their institution	$281,377
Novartis Pharmaceuticals Corporation · Roar A Phase II Open Label Study in Subjects With Braf V600e Mutated Rare Cancers With Several Histologies To Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib · 2021	Their institution	$275,019
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Tak-228 (Mln-0128) in Combination With Metformin in Patients With Advanced Cancers · 2020	Their institution	$269,728
Bayer HealthCare Pharmaceuticals Inc. · Bay1217389 Mps1 Inh Fu (Imidazo) · 2019	Their institution	$265,370
Incyte Corporation · A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of Incb054828 in Subjects With Advanced Malignancies · 2022	Their institution	$264,680
AbbVie Inc. · 2020	Their institution	$253,829
Genmab A/S · A First-in-Human, Open-Label, Dose Escalation Trial To Evaluate the Safety and Antitumor Activity of Gen1057 in Subjects With Malignant Solid Tumors · 2025	Their institution	$252,936
Hoffmann-La Roche Limited · Blu667 1101 Arrow Ongoing · 2023	Their institution	$250,235
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2022	Their institution	$247,055
Bayer HealthCare Pharmaceuticals Inc. · Open-Label Phase 1 First-in-Human Dose Escalation and Expansion Study To Evaluate the Safety Tolerability Maximum Tolerated Or Administered Dose Pharmacokinetics Pharmacodynamics and Tumor Response Profile of the Ildr2 Function-Blocking Antibody Bay1905254 in Patients With Advanced Solid Tumors · 2020	Their institution	$240,778
PFIZER INC. · A Twopart Phase 1ab Openlabel Multicenter Trial Evaluating Pharmacokinetics Safety and Efficacy of Pf 07284890 Arry 461 in Participants With Braf V600 Mutant Solid Tumors With and Without Brain Involvement · 2021	Their institution	$213,378
Eli Lilly and Company · Expanded Access Global Study for Loxo-292 - Title Pending · 2020	Their institution	$210,736
ABBVIE INC. · A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of Abbv-927 and Abbv-181, An Immunotherapy, in Subjects With Advanced Solid Tumors · 2021	Their institution	$210,412
Eli Lilly and Company · A Phase 1a/1b Trial of Ly3962673 in Participants With Kras G12d-Mutant Solid Tumors · 2025	Their institution	$204,024
Foundation Medicine, Inc. · Foundationoneliquiddx-Amc-Pro-20-2130 · 2023	Their institution	$202,500
ABBVIE INC. · A Study of Abbv-927 and Abbv-181, An Immunotherapy, in Participants With Advanced Solid Tumors · 2022	Their institution	$192,500
PFIZER INC. · A Twopart Phase 1ab Openlabel Multicenter Trial Evaluating Pharmacokinetics Safety and Efficacy of Pf 07284890 Arry 461 in Participants With Braf V600 Mutant Solid Tumors With and Without Brain Involvement · 2022	Their institution	$185,172
BeiGene AUS Pty Ltd · A Phase 1b, Open-Label, Dose-Escalation and Expansion Study To Investigate the Safety, Pharmacokinetics and Antitumor Activities of A Raf Dimer Inhibitor Bgb-283 in Combination With Mek Inhibitor Pd-0325901 in Patients With Advanced Or Refractory Solid Tumors · 2022	Their institution	$177,891
AstraZeneca Pharmaceuticals LP · A Phase 1, Open-Label, Dose-Escalation and Expansion Study of Medi1191 Administered Intratumorally As Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors · 2023	Their institution	$166,711
Incyte Corporation · The Purpose of This Study Is To Evaluate Incb186748 in Participants With Advanced Or Metastatic Solid Tumors With Kras G12d Mutation. · 2025	Their institution	$163,352
Amgen Inc. · Amg 404 - Fih and China 20180143 · 2019	Their institution	$156,254
Bayer HealthCare Pharmaceuticals Inc. · Bay1905254 Ildr2 Ph1 Fim · 2019	Their institution	$154,194
Amgen Inc. · 2021	Their institution	$149,831
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2019	Their institution	$142,224
BeOne Medicines Ltd. · A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Bgb-B2033, Alone Or in Combination With Tislelizumab, in Participants With Selected Advanced Or Metastatic Solid Tumors · 2025	Their institution	$133,776
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl102 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2022	Their institution	$133,509
Novartis Pharmaceuticals Corporation · A Phase I Multicenter Open Label Dose Escalation and Expansion Study of Pca062 Administered Intravenously in Adult Patients With Pcad Positive Tumors · 2019	Their institution	$132,501
Incyte Corporation · Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Incagn01876 Combined With Immune Therapies in Advanced Or Metastatic Malignancies · 2020	Their institution	$127,500
Incyte Corporation · An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of Incb059872 in Participants With Relapsed Or Refractory Ewing Sarcoma · 2019	Their institution	$125,770
Foundation Medicine, Inc. · Foundationoneliquiddx-Amc-Pro-20-2130 · 2021	Their institution	$122,500
Eli Lilly and Company · A Phase 1a/1b Study of the Pan-Kras Inhibitor Ly4066434 in Participants With Kras Mutant Solid Tumors · 2025	Their institution	$122,263
Merck Sharp & Dohme LLC · A Phase 2 Study To Evaluate the Efficacy and Safety of Belzutifan Mk-6482, Formerly Pt2977 Monotherapy in Participants With Advanced Pheochromocytoma,Paraganglioma Ppgl, Pancreatic Neuroendocrine Tumor Pnet, Von Hippel-Lindau Vhl Disease-Associate · 2025	Their institution	$122,022
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2023	Their institution	$120,142
Eli Lilly and Company · A Phase 1 Study of Oral Loxo-260 in Patients With Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation Refractory To Selective Ret Inhibitors · 2022	Their institution	$118,977
Bayer HealthCare Pharmaceuticals Inc. · A Phase 1 Open-Label First-in-Human Multi-Center Study To Evaluate the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of Thorium-227 Labeled Antibodychelator Conjugate Bay 2701439 in Participants With Advanced Her2-Expressing Tumors · 2021	Their institution	$118,028
Novartis Pharmaceuticals Corporation · Roar A Phase II Open Label Study in Subjects With Braf V600e Mutated Rare Cancers With Several Histologies To Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib · 2022	Their institution	$117,833
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2020	Their institution	$106,863
Eli Lilly and Company · Expanded Access for the Treatment of Cancers With Rearranged During Transfection (Ret) Activation · 2022	Their institution	$105,408
Incyte Corporation · A Study To Evaluate Incb186748 in Participants With Advanced Or Metastatic Solid Tumors With Kras G12d Mutation · 2025	Their institution	$101,910
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Tak-228 (Mln0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies · 2020	Their institution	$96,883
AstraZeneca Pharmaceuticals LP · A Phase 1, Open-Label, Dose-Escalation and Expansion Study of Medi1191 Administered Intratumorally As Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors · 2020	Their institution	$91,371
Exelixis Inc. · Phase 1 Dose-Escalation, Dose-Finding, and Expansion Study of Xl495 in Solid Tumors · 2025	Their institution	$87,433
Novartis Pharmaceuticals Corporation · Roar A Phase II Open Label Study in Subjects With Braf V600e Mutated Rare Cancers With Several Histologies To Investigate the Clinical Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib · 2023	Their institution	$85,908
Eli Lilly and Company · Expanded Access Global Study for Loxo-292 - Title Pending · 2021	Their institution	$85,072
PFIZER INC. · An Openlabel Phase 1 Study To Evaluate Pf08046037 As Monotherapy and Part of Combination Therapy in Participants With Advanced Malignancies · 2025	Their institution	$84,042
Bayer HealthCare Pharmaceuticals Inc. · A Phase 1 Open-Label First-in-Human Multi-Center Study To Evaluate the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of Thorium-227 Labeled Antibodychelator Conjugate Bay 2701439 in Participants With Advanced Her2-Expressing Tumors · 2020	Their institution	$83,569
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2019	Their institution	$81,781
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2021	Their institution	$81,505
AstraZeneca Pharmaceuticals LP · A Phase 1, Open-Label, Dose-Escalation and Expansion Study of Medi1191 Administered Intratumorally As Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors · 2022	Their institution	$78,634
Hoffmann-La Roche Limited · Blu667 1101 Arrow Ongoing · 2024	Their institution	$77,774
Incyte Corporation · An Open-Label, Multicenter, Rollover Study To Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib · 2022	Their institution	$72,377
Genentech, Inc. · A Phase Ia/Ib Dose Escalation and Dose Expansion Study Evaluating Gdc-7035 for Patients With G12d Mu · 2025	Their institution	$71,962
Exelixis Inc. · A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl102 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2021	Their institution	$70,849
Deciphera Pharmaceuticals Inc. · A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of Dcc-3084 As Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors Driven By the Mapk Pathway · 2024	Their institution	$68,825
Daiichi Sankyo Inc. · 2025	Their institution	$65,350
Sumitomo Pharma America, Inc. · An Open-Label, Phase 1 Dose Escalation and Phase 2 Dose Expansion Study To Assess Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Smp-3124lp in Adults With Advanced Solid Tumors · 2025	Their institution	$63,495
Blueprint Medicines Corporation · Phase 1/2 Study of the Highly-Selective Ret Inhibitor, Pralsetinib (Blu-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors (Arrow) · 2021	Their institution	$62,837
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2019	Their institution	$59,826
Gilead Sciences, Inc. · A Phase 2 Multi-Arm Study of Magrolimab in Patients With Solid Tumors · 2021	Their institution	$57,531
BeiGene AUS Pty Ltd · A Phase 1b Open Label Dose Escalation and Expansion Study To Investigate the Safety Pharmacokineticx and Antitumor Activities of A Raf Dimer Inhibitor Bgb-283 in Combination With Mik Inhibitor Pd-0325901 in Patients With Advanced Or Refractory Solid Tumors · 2020	Their institution	$57,250
Clovis Oncology, Inc. · A Phase 1/2, Multicenter, Open-Label, Non-Randomized Study To Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177lu-Fap-2286 in Patients With An Advanced Solid Tumor · 2022	Their institution	$56,250
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl092 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2020	Their institution	$54,893
Exelixis Inc. · Phase 1 Dose-Escalation Study of Xb628 in Recurrent Advanced Or Metastatic Solid Tumors · 2025	Their institution	$53,363
Helsinn Healthcare SA · Phase I/II Study of the Selective Ret Inhibitor Tas0953/Hm06 in Patients With Advanced Solid Tumors With Ret Gene Abnormalities · 2021	Their institution	$51,250
Hoffmann-La Roche Limited · Zelboraf Rollover Study · 2019	Their institution	$51,160
AstraZeneca Pharmaceuticals LP · A Modular Phase I Iia Open-Label Multi-Centre Study To Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of Azd0022 Monotherapy and in Combination With Anti-Cancer Agents in Participants With Tumours Harbouring A Krasg12d Mutation · 2025	Their institution	$49,050
PFIZER INC. · A Phase 1 Dose Escalation and Expansion Study To Evaluate Safety Tolerability Pharmacokinetic Pharmacodynamic and Antitumor Activity of Pf07820435 As Monotherapy and in Combination in Participants With Advanced Solid Tumors · 2024	Their institution	$48,459
Exelixis Inc. · A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl102 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2023	Their institution	$48,399
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2020	Their institution	$48,324
Amgen Inc. · Amg 404 - Fih and China 20180143 · 2020	Their institution	$44,256
Incyte Corporation · An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of Incb059872 in Participants With Relapsed Or Refractory Ewing Sarcoma · 2020	Their institution	$43,609
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Tak-228 (Mln0128) in Combination With Carboplatin Plus Paclitaxel in Patients With Advanced Malignancies · 2019	Their institution	$41,843
Deciphera Pharmaceuticals Inc. · A Master Protocol for the Multi-Cohort, Open-Label, Phase 1/2 Study of Dcc-3084 As Monotherapy and in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors Driven By the Mapk Pathway · 2025	Their institution	$41,090
Takeda Pharmaceuticals U.S.A., Inc. · A Phase I Study of Tak-228 (Mln-0128) in Combination With Metformin in Patients With Advanced Cancers · 2019	Their institution	$40,665
Incyte Corporation · An Open-Label, Multicenter, Rollover Study To Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Pemigatinib · 2023	Their institution	$38,984
BeiGene, Ltd. · A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Bgb-B2033, Alone Or in Combination With Tislelizumab, in Patients With Selected Advanced Or Metastatic Solid Tumors · 2024	Their institution	$38,284
Bayer HealthCare Pharmaceuticals Inc. · An Open-Label First-in-Human Multi-Center Study To Evaluate the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of A Thorium-227 Labeled Antibody-Chelator Conjugate Bay 2287411 Injection in Patients With Solid Tumors Known To Express Mesothelin · 2021	Their institution	$36,693
Novartis Pharmaceuticals Corporation · A Phase I/Ib Study of Subcutanious Recombinent Niz985 in Combination With Spartalizumab (Pdr001) in Patient With Check Point Inhibitor (Cpi) Relapsed Advance Solid Tumor and Lympoma · 2021	Their institution	$36,216
Amgen Inc. · P1b/2 Solid Tumor Hepatic Injection Safety. · 2020	Their institution	$35,214
PFIZER INC. · A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies · 2020	Their institution	$33,820
AstraZeneca Pharmaceuticals LP · A Phase 1, Open-Label, Dose-Escalation and Expansion Study of Medi1191 Administered Intratumorally As Monotherapy and in Combination With Durvalumab in Subjects With Advanced Solid Tumors · 2021	Their institution	$31,373
Helsinn Healthcare SA · Phase I/II Study of the Selective Ret Inhibitor Tas0953/Hm06 in Patients With Advanced Solid Tumors With Ret Gene Abnormalities · 2023	Their institution	$30,208
Bayer HealthCare Pharmaceuticals Inc. · An Open-Label First-in-Human Multi-Center Study To Evaluate the Safety Tolerability Pharmacokinetics and Anti-Tumor Activity of A Thorium-227 Labeled Antibody-Chelator Conjugate Bay 2287411 Injection in Patients With Solid Tumors Known To Express Mesothelin · 2020	Their institution	$27,219
Exelixis Inc. · A Phase 1b Dose Escalation Study of Cabozantinib (Xl184) Administered Alone Or in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2024	Their institution	$26,857
Bayer HealthCare Pharmaceuticals Inc. · Msln-Ttc First-in-Man Study (Dose-Escalation + Expansion) · 2019	Their institution	$25,625
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2023	Their institution	$25,317
BeiGene AUS Pty Ltd · A Phase 1b, Open-Label, Dose-Escalation and Expansion Study To Investigate the Safety, Pharmacokinetics and Antitumor Activities of A Raf Dimer Inhibitor Bgb-283 in Combination With Mek Inhibitor Pd-0325901 in Patients With Advanced Or Refractory Solid Tumors · 2021	Their institution	$23,824
Amgen Inc. · 2022	Their institution	$22,777
PFIZER INC. · A Phase 1 Dose Escalation and Expansion Study To Evaluate Safety Tolerability Pharmacokinetic Pharmacodynamic and Antitumor Activity of Pf07820435 As Monotherapy and in Combination in Participants With Advanced Solid Tumors · 2025	Their institution	$22,750
BeiGene AUS Pty Ltd · A Phase 1b, Open-Label, Dose-Escalation and Expansion Study To Investigate the Safety, Pharmacokinetics and Antitumor Activities of A Raf Dimer Inhibitor Bgb-283 in Combination With Mek Inhibitor Pd-0325901 in Patients With Advanced Or Refractory Solid Tumors · 2023	Their institution	$21,123
Foundation Medicine, Inc. · Foundationoneliquiddx-Amc-Pro-20-2130 · 2022	Their institution	$20,500
PFIZER INC. · A Phase 1 Openlabel Study To Investigate Pf08046876 in Adult Participants With Advanced Solid Tumors · 2025	Their institution	$20,400
Incyte Corporation · A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of Incb054828 in Subjects With Advanced Malignancies · 2021	Their institution	$19,592
Eli Lilly and Company · 2023	Their institution	$19,443
Eli Lilly and Company · A Phase 1a/1b Trial of Ly3962673 in Participants With Kras G12d-Mutant Solid Tumors · 2024	Their institution	$19,250
Bayer HealthCare Pharmaceuticals Inc. · Bay94-9343 Solid Tumor Multi Cohort Trial · 2019	Their institution	$19,031
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2022	Their institution	$17,307
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2023	Their institution	$17,187
Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025	Their institution	$15,944
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2021	Their institution	$14,513
Amgen Inc. · P1b/2 Solid Tumor Hepatic Injection Safety. · 2021	Their institution	$14,200
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2 Multicenter Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2022	Their institution	$12,329
PFIZER INC. · A Twopart Phase 1ab Openlabel Multicenter Trial Evaluating Pharmacokinetics Safety and Efficacy of Pf 07284890 Arry 461 in Participants With Braf V600 Mutant Solid Tumors With and Without Brain Involvement · 2023	Their institution	$12,208
Amgen Inc. · 20190136 - Container. · 2021	Their institution	$10,371
Eli Lilly and Company · A Phase 1/2 Study of Oral Selpercatinib (Loxo-292) in Patients With Advanced Solid Tumors, Including Ret Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With Ret Activation (Libretto-001) · 2024	Their institution	$9,783
Merck Sharp & Dohme LLC · A Phase 2, Open-Label, Multi-Center, Safety and Efficacy Study of Prt3789 in Combination With Pembrolizumab in Patients With Advanced Or Metastatic Solid Tumors With A Smarca4 Mutation · 2025	Their institution	$8,280
Hoffmann-La Roche Limited · Zelboraf Rollover Study · 2020	Their institution	$8,077
Incyte Corporation · An Open Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of Incb059872 in Participants With Relapsed Or Refractory Ewing Sarcoma · 2021	Their institution	$7,466
Amgen Inc. · 20190136 - Container. · 2022	Their institution	$6,586
Bayer Healthcare Pharmaceuticals Inc. · A Phase 2 Open-Label Basket Study To Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor Bay 2927088 in Participants With Metastatic Or Unresectable Solid Tumors With Her2-Activating Mutations · 2025	Their institution	$6,006
Exelixis Inc. · A Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of Xl102 As Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced Or Metastatic Solid Tumors · 2024	Their institution	$5,784
Amgen Inc. · 20190136 - Container. · 2023	Their institution	$5,296
PFIZER INC. · A Phase 1 Openlabel Multicenter Dosefinding Pharmacokinetic Safety and Tolerability Study of Pf07265807 in Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies · 2024	Their institution	$5,133
Bayer HealthCare Pharmaceuticals Inc. · Open-Label Phase 1 First-in-Human Dose Escalation and Expansion Study To Evaluate the Safety Tolerability Maximum Tolerated Or Administered Dose Pharmacokinetics Pharmacodynamics and Tumor Response Profile of the Ildr2 Function-Blocking Antibody Bay1905254 in Patients With Advanced Solid Tumors · 2021	Their institution	$5,012
BeiGene USA, Inc. · A Phase 1b, Open-Label, Dose-Escalation and Expansion Study To Investigate the Safety, Pharmacokinetics and Antitumor Activities of A Raf Dimer Inhibitor Bgb-283 in Combination With Mek Inhibitor Pd-0325901 in Patients With Advanced Or Refractory Solid Tumors · 2022	Their institution	$3,641
Amgen Inc. · A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Amg 410 Alone and in Combination With Other Agents in Participants With Kras Altered Advanced Or Metastatic Solid Tumors · 2025	Their institution	$2,945
Novartis Pharma AG · Cdrb436x2201 · 2023	Their institution	$2,700
PFIZER INC. · Oncology Portfolio Clinical Publication Program · 2021	This clinician	$2,540
Incyte Corporation · A Phase 1/2, Open Label, Dose Escalation, Safety and Tolerability Study of Incb054828 in Subjects With Advanced Malignancies · 2023	Their institution	$2,500
JAZZ PHARMACEUTICALS INC. · Emerge-201: A Phase 2, Multicenter, Open-Label Study of Lurbinectedin Efficacy and Safety in Participants With Advanced Or Metastatic Solid Tumors · 2025	Their institution	$2,217
PFIZER INC. · Elranatamab Clinical Publication Program · 2023	This clinician	$1,880
PFIZER INC. · Nirogacestat Clinical Publication Program · 2022	This clinician	$1,600
Novartis Pharmaceuticals Corporation · A Phase I/Ib Study of Subcutanious Recombinent Niz985 ((Het- Il-15) (Il-15 /Sil-15i)) in Combination With Spartalizumab (Pdr001) in Patient With Check Point Inhibitor (Cpi) Relapsed Advance Solid Tumor and Lympoma · 2022	Their institution	$1,562
F. Hoffmann-La Roche AG · Blu667 1101 Arrow Ongoing · 2023	This clinician	$1,551
Amgen Inc. · A Phase 1 Study To Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Amg 404, A Programmed Death-1 (Pd-1) Antibody, in Patients With Advanced Solid Tumors · 2025	This clinician	$1,489
Amgen Inc. · Amg 404 - Fih and China 20180143 · 2021	Their institution	$1,274
Novartis Pharmaceuticals Corporation · Research Related Publications Support · 2020	This clinician	$1,184
Novartis Pharmaceuticals Corporation · A Phase I II Multicenter Open Label Study of Mak683 in Adult Patients With Advanced Malignancies · 2024	Their institution	$1,142
Exelixis Inc. · Study of Cabozantinib in Combination With Atezolizumab To Subjects With Locally Advanced Or Metastatic Solid Tumors · 2021	Their institution	$1,093
ABBVIE INC. · A Phase 1 First-in-Human Study With Abbv-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/Or Refractory Solid Tumors · 2021	Their institution	$927
Novartis Pharmaceuticals Corporation · A Phase I/Ib Study of Subcutanious Recombinent Niz985 ((Het- Il-15) (Il-15 /Sil-15)) in Combination With Spartalizumab (Pdr001) in Patient With Check Point Inhibitor (Cpi) Relapsed Advance Solid Tumor and Lympoma · 2023	Their institution	$560
PFIZER INC. · Gedatolisib Clinical Publication Program · 2022	This clinician	$330
Bayer HealthCare Pharmaceuticals Inc. · Bay1217389 Mps1 Inh Fu (Imidazo) · 2020	Their institution	$280
Amgen Inc. · 2020	Their institution	$231
PFIZER INC. · A Twopart Phase 1ab Openlabel Multicenter Trial Evaluating Pharmacokinetics Safety and Efficacy of Pf 07284890 Arry 461 in Participants With Braf V600 Mutant Solid Tumors With and Without Brain Involvement · 2020	Their institution	$70

Checkups this office reported

Medicare did not publish checkup rates for this clinician.

Medicare’s overall office score: 81.4 / 100; Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.

Professional record

NPI: 1174726384
Licence: TX N6693Texas N6693: Delinquent - Incomplete Registration
Group: Stanford Health Care · Verdi Oncology Tennessee PC
Video visits: Lists video visits
Gender: Male

More record details

Sole proprietor: No
Taxonomy: Medical oncology (207RX0202X); Internal medicine (207R00000X); Federal specialty code 207RH0003X (207RH0003X); Pediatrics (208000000X); Federal specialty code 2080P0207X (2080P0207X)
Mailing address: 300 Pasteur Dr, Stanford, CA, 94305
NPI first listed: 2007-06-06
NPI last updated: 2026-03-11
NPI record certified: 2026-03-11

This is when the NPI record was last certified, not a medical board exam.

Extra NPI addresses: 1515 Holcombe Blvd, Houston, TX, 77030